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Abstract 
A SAR study on derivatives of 2-amino-1-benzyl-4,5-diphenyl-1H-pyrrole-3-carbonitrile 5a 
revealed that the 3-carbonitrile group, vicinal 4,5-diphenyl and N-benzyl side chains of the 
pyrrole are important for the inhibitory potencies of these compounds against members 
representing the three main subclasses of metallo-β-lactamases (MBLs), i.e. IMP-1 
(representing the B1 subgroup), CphA (B2) and AIM-1 (B3). Coupling of 5a with a series of 
acyl chlorides and anhydrides led to the discovery of two N-acylamide derivatives, 10 and 11, 
as the two most potent IMP-1 inhibitors in this series. However, these compounds are less 
effective towards CphA and AIM-1. The N-benzoyl derivative of 5a retained potent in vitro 
activity against each of MBLs tested (with inhibition constants in the low µM range). 
Importantly, this compound also significantly enhanced the sensitivity of IMP-1, CphA- or 
AIM-1-producing cell cultures towards meropenem. This compound presents a promising 
starting point for the development of a universal MBL inhibitor, targeting members of each 
of the major subgroups of this family of enzymes. 
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1. Introduction 
It is well accepted that the global over-use of antibiotics, such as β-lactam antibiotics [1] in 
both humans and livestock is a major cause of the rapid emergence of antibiotic resistance in 
a growing number of pathogens [2, 3]. As a result, there is a dire need for novel classes of 
antibiotics [3, 4]. The continuous search for such compounds appears unavoidable due to the 
ability of pathogens to respond to the evolutionary pressure exerted by these compounds by 
evolving novel resistance strategies. A highly successful strategy involves the use of β-
lactamases, enzymes which hydrolytically degrade β-lactam antibiotics [5-7]. 
β-Lactamases are categorised into four classes: A, B, C and D [8]. The class A, C and D β-
lactamases utilise a nucleophilic serine residue to cleave the β-lactam ring, and hence are 
known as serine-β-lactamases (SBLs) [5, 8]. Inhibitors for the class A and D SBLs have been 
successfully developed and are clinically administered in combination with β-lactam 
antibiotics [5]. On the other hand, the zinc-dependent class B β-lactamases, or metallo-β-
lactamases (MBLs), are not inhibited by any of the clinically available SBL inhibitors [5, 6, 
8, 9]. In addition, the MBLs are capable of hydrolysing a wide range of β-lactam antibiotics, 
including carbapenems such as imipenem (1, Figure 1), which are regarded as ‘last good’ or 
‘last-line’ antibiotics for the treatment of infections caused by antibiotic-resistant bacteria [5, 
6, 8-10]. Moreover, the resistant genes responsible for the expression of these metallo-
enzymes are highly transferable on bacterial mobile genetic elements such as plasmids, and 
have been widely disseminating among pathogenic Gram-negative bacteria [1, 2, 6, 8, 9]. 
Exacerbating the threat of MBLs to health care is the observation these enzymes can alter and 
expand their substrate range easily via mutations, thus adapting to novel antibiotics and 
potentially avoiding inhibitors [11-13]. All of these reasons therefore require the issue of 
MBL-mediated bacterial resistance to be addressed urgently.  
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Figure 1. Chemical structure of Imipenem 1. 
MBLs are subdivided based on their sequence homology, metal ion requirement for activity, 
and substrate selectivity into as many as four sub-classes: B1, B2, B3 and B4 [6, 7, 14-17]. 
The B1 and B3 MBLs are catalytically active with two zinc ions, and exhibit a broad 
substrate profile, whereas the mono-zinc B2 MBLs are solely carbapenemases [6, 14]. Little 
is known about members of the B4 subgroup other than that they may form a catalytically 
active di-metallic centre only in the presence of a substrate [17]. Since none of the B4 
enzymes has yet been associated with antibiotic resistance they have been excluded from the 
present study. 
Since its discovery in 1988 in Japan, the plasmid-acquired B1 MBL Imipenemase 1 (IMP-1) 
has been detected world-wide [9]. The global emergence of IMP-1, combined with extensive 
structural and kinetics information of this enzyme reported in the literature, make it a suitable 
starting point in the quest to develop novel, clinically useful MBL inhibitors [18-20]. CphA is 
an MBL from the pathogenic Aeromonas hydrophilia. It belongs to the B2 subclass of MBL 
and is of interest because it has a narrow specificity profile, efficiently hydrolysing only 
carbapenems [21]. Another MBL of clinical relevance and interest to us is the recently 
discovered Adelaide Imipenemase (AIM-1) [22], so named after its place of isolation in 
Australia [23]. AIM-1 is currently the only known B3 MBL encoded on a mobile transferable 
genetic element [23], and it can easily be mutated to become an efficient catalyst that 
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hydrolyses members of all major β-lactam groups [11]. While there have been several 
inhibitors of IMP-1 reported [18, 19, 24-29] and some CphA inhibitors [21, 30, 31], thus far 
there are no known inhibitors of AIM-1. 
As part of our program into the development of MBL inhibitors, we identified pyrrole 5a as a 
competitive inhibitor of IMP-1, possessing an inhibition constant (Ki) of 21 ± 10 µM [27]. 
Docking simulations of compound 5a bound in the active site of IMP-1 suggested 
hydrophobic interactions of the 4,5-diphenyl groups of 5a with Val25, Trp28 and Val31, 
along with hydrogen bonding stabilisations between (i) the amino functional group of 5a and 
His139 (N-N distance 3.03 Å) and (ii) the cyano nitrogen of 5a and Lys161 (N-N distance 
3.10 Å). Curiously, no interaction between 5a and either of the zinc ions in the active site of 
IMP-1 was predicted by the modelling program [27] (Figure 2).  
 
Figure 2. Computational model of pyrrole 5a docked into the active site of IMP-1 as 
predicted by MolDock [32]. Atom colours: carbon on ligand in olive green, carbon on IMP-1 
in grey, nitrogen in blue, oxygen in red and hydrogen in white. The Zn2+ ions are shown as 
red spheres. The dashed, green lines represent hydrogen bonds. Adapted from [27]. 
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To further explore the potential mode of binding of 5a in the active site of IMP-1, to 
determine SAR relationships, and to examine specificity of this inhibitor with respect to the 
B2 and B3 MBLs CphA and AIM-1, respectively, we decided to examine the effects of (i) 
substituting the vicinal 4,5-diphenyl rings with different aromatic and aliphatic groups; (ii) 
acylating the 2-amino group with various aliphatic and aromatic groups; (iii) modifying the 
3-carbonitrile group, and (iv) varying the chain length of the phenyl group attached to the 
pyrrole nitrogen. 
 
2. Chemistry 
The synthetic routes to compounds 5-19 are shown in Schemes 1-5. Syntheses of the 2-
amino-3-cyanopyrroles were accomplished by treating α-hydroxyketones 2a-c with suitable 
primary amines 3a-f in hot toluene in the presence of a catalytic amount of trichloroacetic 
acid. After initial formation of the unisolated α-aminoketones 4, addition to the reaction 
mixture of malononitrile led to ring-closure and heterocycle formation [33, 34]. Using this 
approach, pyrroles 5a-g were prepared in good yields (Scheme 1). Pyrrole 5h could not be 
prepared by this method. Instead, 5h was prepared in two steps as shown in Scheme 2. 
Heating benzoin 2a with aniline 3f gave the α-aminoketone 6, which was isolated in 63% 
yield. Subsequent treatment of 6 with malononitrile and sodium ethoxide in ethanol [34] gave 
the desired N-phenylpyrrole 5h in 60% yield. 
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Scheme 1. Reagents and conditions: (a) Cl3CCO2H, toluene, ∆, 4-6 h; (b) CH2(CN)2, ∆, 
overnight. 5a (67%); 5b (61%); 5c (59%); 5d (63%); 5e (78%); 5f (53%); 5g (78%); 5h 
(0%). 
 
 
Scheme 2. Reagents and conditions: (a) Cl3CCO2H, toluene, ∆ (63%); (b) CH2(CN)2, NaOEt, 
EtOH, ∆ (60%). 
 
Initial attempts to acylate the poorly nucleophilic 2-amino group of 5a with one molar 
equivalent of various aromatic and aliphatic acid chlorides led in some cases to poor yields of 
the desired monoacylated derivatives, For example, attempted acylation of 5a with benzoyl 
chloride following the method of Müller et al. [35] gave only 37% yield of the benzamide 8b, 
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along with 52% recovered starting material. Repeating the reaction with an excess of acid 
chloride or acid anhydride in refluxing toluene led to diacylation, resulting in the formation 
of the imides 7a-d in good yields (Scheme 3). These imides could be converted to their 
corresponding amides 8a-d by partial deacylation using methanolic potassium carbonate 
(Scheme 3). 
 
Scheme 3. Reagents and conditions: (a) (i) Ac2O, ∆, 3 h, (ii) 25% NH3, 7a (79%) or RCOCl, 
Et3N, toluene, ∆, overnight, 7b (76%); 7c (86%); 7d (93%); (b) K2CO3, MeOH, r.t., 1 h, 8a 
(68%); 8b (56%); 8c (95%); 8d (87%). 
 
Imides 7 were only formed in some cases from pyrrole 5a using the acylation conditions 
described in Scheme 3. In other cases only the mono-acylated amides were obtained (i.e., 11, 
14 and 15) and for some acylating agents a mixture of mono- (i.e., 10 and 13) and diacylated 
products resulted (i.e., 9 and 12). The reaction of pyrrole 5a with phthalic anhydride gave the 
expected imide 16 (Figure 3). 
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Figure 3. Amide and imide products arising from the acylation of pyrrole 5a. Reaction 
conditions used were the same as those described in Scheme 3. 
 
To investigate the effect that the nitrile group of 5a has on its inhibitory activity, two 
transformations of this group were performed. The first, involving the hydrolysis of the nitrile 
to the carboxamide proceeded uneventfully using hot polyphosphoric acid (Scheme 4) [36]. 
The second derivatisation of the nitrile group of 5a, a 1,3-dipolar cycloadddtion with azide to 
give a tetrazole, proved to be more troublesome. Attempted reaction of 5a with sodium azide 
in the presence of either triethylammonium hydrogensulfate in hot toluene [37], or with 
sodium azide and ammonium chloride in hot N,N-dimethylformamide [38] failed. The 
desired transformation was finally achieved, albeit in low yield, by reacting pyrrole 5a with 
aluminium triazide, formed in situ using trimethylsilyl azide and trimethylaluminium, in hot 
toluene [39] (Scheme 4). 
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Scheme 4. Reagents and conditions: (a) (i) P2O5, H3PO4, ∆, 5 h; (ii) 25% NH3 (79%); (b) 
TMSN3, Me3Al, toluene, ∆, 28 h (26%). 
 
The final desired transformation of 5a was removal of the N-benzyl group, to determine its 
role in the inhibitory activity of this compound. This reaction also proved to be problematic: 
attempted hydrogenolysis of the N-benzyl group of 5a using hydrogen gas over palladium-
carbon [40] failed, as did attempted debenzylation with aluminium trichloride [41]. In both 
cases only starting material was recovered. The required product 19 was ultimately obtained 
by debenzylation of the N-(4-methoxybenzyl) derivative 5d using aluminium trichloride in 
anisole [42]. 
 
Scheme 5. Reagents and conditions: (a) AlCl3, PhOMe, ∆, 17 h (36%). 
3. Results and Discussion 
Initial studies of the structure-activity relationship of the aminopyrroles 5a-h focused on 
IMP-1 inhibition. Table 1 shows the inhibitory activity of compounds 5a-h, all measured at 
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10 µM, against IMP-1. It can be seen that replacement of the geminal diphenyl groups of the 
starting molecule 5a with methyl groups (5b) leads to significant loss of potency. Substitution 
of the phenyl groups with furan rings does not increase potency (5c), nor does the addition of 
a 4-methoxy group to the N-benzyl moiety (5d). Extending the N-benzyl group of 5a by one, 
two or three methylenes (compounds 5e, 5f and 5g, respectively) results in marked loss of 
inhibitory activity, and activity is abolished when the N-benzyl group of 5a is replaced with a 
an N-phenyl group (5h). These results indicate the crucial role that the benzylic group (benzyl 
or 4-methoxybenzyl) on the pyrrole nitrogen plays in maintaining inhibitory activity against 
IMP-1, and the importance of the two aromatic groups on the 4- and 5-positions of the 
pyrrole. 
Table 1. Inhibition data for 2-amino-3-cyanopyrroles 5a-h (10 µM) against IMP-1 activity. 
Inhibitor % Inhibition Inhibitor % Inhibition 
5a 26.0 ± 2.7 5e 4.8 ± 0.8 
5b 2.3 ± 3.3 5f 4.1 ± 0.8 
5c 23.2 ± 3.9 5g 8.7 ± 1.1 
5d 20.1 ± 4.3 5h 0 
 
For the imide (7a-d) and amide (8a-d) derivatives of 5a, the data in Table 2 show that the 
aliphatic amides and imides were less active against IMP-1 than 5a. The aromatic imide (7b) 
and aromatic amide (8b), however, were both more potent than 5a. The dibenzoyl imide (7b) 
was later shown to exhibit a mixed inhibition mode against IMP-1, with a less potent Ki value 
(see below). To test where the imide (7b) was hydrolysing during the course of the assay to 
the amide (8b), 7b was incubated with IMP-1 overnight. No trace of 8b was detected in the 
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mixture using electrospray ionisation mass spectrometry (ESI-MS), suggesting that the imide 
7b is stable towards hydrolysis by the enzyme (data not shown). 
Other than the dibenzoyl imide 7b and the amide 8b, the 4-nitrobenzamide (10), the 3-
nitrobenzamide (14), the 4-benzoylbenzamide (11) and the 3,5-dimethylbenzamide derivative 
(13) all showed inhibitory activity greater than 5a. Additional kinetic data for these 
compounds are discussed below.  
Table 2. Inhibition data for N-acyl amides and N,N-diacyl imides 7-16 (10 µM) against IMP-
1 activity. For comparison, compound 5a showed inhibition of 26% at 10 µM (Table 1). 
Inhibitor % Inhibition Inhibitor % Inhibition 
7a 18.6 ± 4.8 9 20.2 ± 3.4 
7b 48.0 ± 5.9 10 36.9 ± 2.4 
7c 17.1 ± 3.4 11 44.3 ± 3.3 
7d 14.3 ± 2.4 12 13.3 ± 2.4 
8a 16.1 ± 6.6 13 32.3 ± 4.7 
8b 50.9 ± 2.5 14 48.7 ± 1.9 
8c 21.0 ± 2.5 15 23.3 ± 3.7 
8d 8.2 ± 4.5 16 20.3 ± 3.7 
 
Derivatives with modifications to the 3-cyano group (compounds 17-18) and deletion of the 
N-benzyl group (19) were also examined (Table 3). Conversion of the cyano group of 5a to 
the primary amide gave 17, which was devoid of activity. The tetrazole 18, formed by 
cycloaddition of azide to the nitrile group of 5a, was poorly active, as was the de-N-
benzylated compound 19. These results indicate that the 3-nitrile group of 5a is necessary for 
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potent activity of these inhibitors. Similarly, the N-benzyl group on the pyrrole is optimal 
(compare 19 with 5d-h) 
Table 3. Inhibition data for pyrrole derivatives 17-19 (10 µM) against IMP-1 activity. 
Inhibitor % Inhibition Inhibitor % Inhibition Inhibitor % Inhibition 
17 0 18 8.7 ± 1.3 19 12.0 ± 2.6 
 
The compounds that showed inhibitory activity higher than that of 5a were further examined 
to determine their inhibition constants and their modes of inhibition (competitive or 
uncompetitive) (Table 4). The most potent competitive inhibitor of the series is the 4-
nitrobenzamide 10, with a Kic value of 1.24 µM. The 4-benzoylbenzamide 11 is also a potent 
inhibitor, but its mode of inhibition is uncompetitive (Kiuc 1.52 µM). Benzamides 8b, 13 and 
14 are slightly more potent than 5a, but each has a mixed mode of inhibitory activity, with 
their uncompetitive inhibition constants being smaller than their competitive counterparts. 
Imide 7b showed a modest Kiuc value of 55 µM. 
These results suggest that the presence of an N-aroyl group appending the 3-amino group of 
5a can in some cases improve these compounds’ potencies against IMP-1. Notable is the 
effect of these compounds on the mode of inhibition. For example, the 3-nitrobenzamide 
derivative 14 inhibits potently and mainly uncompetitively, whereas the isomeric 4-nitro 
analogue is exclusively a competitive inhibitor, as is the 4-benzoylbenzamide derivative 11. 
The absence of a substituent (8b) or the presence of a 3,5-dimethylbenzamide group (13) 
leads to mixed mode inhibition. Thus, relatively minor modifications have a significant 
influence on the mode of their binding interactions. This observation, while previously noted 
with other MBL inhibitors [17-22] may also be a reflection of conformational dynamics and 
fitness landscape of MBLs [11-13, 43, 44]. 
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Table 4. Competitive (Kic) and uncompetitive (Kiuc) inhibition constants of inhibitors 5a, 7b, 
8b, 10, 11, 13 and 14 against IMP-1. 
Inhibitor Structure Kic (µM) Kiuc (µM) 
5a 
 
21 ± 10 a - 
7b 
 
468 ± 6 55 ± 19 
8b 
 
10.7 ± 9.3 4.3 ± 1.8 
10 
 
1.24 ± 0.59 - 
11 
 
- 1.52 ± 0.36 
13 
 
20.2 ± 10.9 7.8 ± 2.5 
14 
 
23.7 ± 25.2 3.3 ± 0.8 
a
 Data from [27] 
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The ultimate goal from a clinical point of view is the development of an inhibitor that is 
effective against MBLs from each of the subgroups, a so-called universal MBL inhibitor. The 
structural and functional differences between the three subclasses of MBLs have made the 
search for such broad-spectrum inhibitors challenging, and efforts towards this goal have met 
with limited success. Several compounds have been shown to inhibit more than one subclass 
of MBL. Schofield’s group has reported that thiomandelic acid 20 is a potent inhibitor of 
several MBLs of the B1 and B3 subclasses, but not of CphA, a B2 MBL [45]. Further 
development of inhibitors containing a thiol group led to the di(mercaptomethyl)benzoic acid 
21 and the mercaptoacetophenone 22 as compounds with submicromolar inhibition against 
all classes of MBL [31]. The same group later reported cyclic boronates as broad-spectrum 
MBL inhibitors, e.g. 23, which are able to inhibit various MBLs and SBLs. Inhibitor 23 
showed low- or submicromolar activity against a number of B1 subclass MBLs, as well as the 
B2 MBL CphA. However, no activity for the cyclic boronates was reported for B3 MBLs 
[46]. 
 
Here, compounds 5a, 8b, 10 and 11 were additionally tested for inhibitory activity against the 
B2 subclass MBL CphA and the B3 subclass MBL AIM-1. Results are summarised in Table 
5. The 4-nitrobenzamide compound 10 showed good activity against the B3 enzyme AIM-1, 
but was devoid of activity against the B2 enzyme CphA. On the other hand compound 11, 
while a potent IMP-1 inhibitor, was only weakly active against CphA, and not at all active 
against AIM-1. In contrast, compound 5a was shown to be a potent inhibitor of both CphA 
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and AIM-1, binding in a predominantly uncompetitive manner to the former and 
competitively to the latter. Similarly, the benzamide derivative 8b was a potent mixed mode 
inhibitor of CphA, and a potent competitive inhibitor of AIM-1. The observed differences in 
binding modes reflect both structural differences among MBLs from different subgroups and 
conformational dynamics that may facilitate alternative binding modes. The modes of binding 
of the thiol inhibitors 20-22 in the active site of MBLs involves direct binding of the thiolate 
group to the zinc ion(s). For the cyclic boronate 23, the oxygens attached to boron bind to 
zinc, and the group acts as a mimic of the tetrahedral intermediate involved in β-lactam 
hydrolysis [31, 46]. The modes of binding of compounds 5a and 8b have not yet been 
visualised but the structure of these molecules suggests that a direct coordination to the metal 
ion(s) in the active site may not be essential for a potent inhibitor. This interpretation is in 
agreement with recent in vitro evolution studies that demonstrated that residues essential for 
substrate, and by analogy, inhibitor recognition may not be close to the immediate 
coordination sphere of the catalytically essential metal ions [11-13, 43, 44, 47-49]. 
Identifying and visualising such remote inhibitor binding sites may thus provide an attractive 
target for the design of universal MBL inhibitors, and compounds such as 5a and 8b may 
play a pivotal in this endeavour. Efforts towards these goals are currently in progress. 
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Table 5. Comparison of inhibitory activities of compounds 5a, 8b, 10 and 11 against 
representatives of each subclass of MBL. 
Inhibitor IMP-1 (B1) CphA (B2) AIM-1 (B3) 
Kic (µM) Kiuc (µM) Kic (µM) Kiuc (µM) Kic (µM) Kiuc (µM) 
5a 21 ± 10 - 52 ± 7 5.5 ± 0.8 2.2 ± 0.3 12.5 ± 2.2 
8b 10.7 ± 9.3 4.3 ± 1.8 11 ± 4 9 ± 2 1.6 ± 0.4 13 ± 13 
10 1.24 ± 0.59 - - - 10.9 ± 2.7 47 ± 17 
11 - 1.52 ± 0.36 872 ± 50 161 ± 32 - - 
 
While the design of potent broad-spectrum inhibitors of MBLs is a crucial step in the fight 
against the spread of antibiotic resistance a promising compound needs to display both 
effective in vitro inhibition of MBLs and in vivo enhancement of the sensitivity of MBL-
producing pathogens towards β-lactam antibiotics. We thus measured the MIC values of 
IMP-1-, CphA- and AIM-1-producing E. coli cultures in the absence and presence of 
compounds 5a, 8b, 10 and 11. The results are summarised in Table 6. While none of these 
compounds inhibit bacterial growth in the absence of meropenem (Supporting Information, 
Figure S1), each of them inhibited cell growth in the presence of this antibiotic, consistent 
with a synergetic effect between the compounds tested and the antibiotic (Supporting 
Information, Figure S2). Among the four compounds tested 8b displayed the strongest effect 
among the representatives of the three major MBL subclasses. Overall, a reasonable 
agreement between inhibition constants (Table 5) and MIC values (Table 6) is observed. For 
instance, compounds 10 and 11, which are either poor or no inhibitors for CphA and AIM-1 
(Table 5), have also very modest effect on corresponding MIC values (Table 6). In contrast, 
compounds 5a and 8b, the only compounds identified here as “universal” MBL inhibitors 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
(Table 5), also have a significant effect on the MIC values of cell cultures expressing any of 
the three MBLs tested here (Table 6). This correlation is most significant for compound 8b. 
Relative to the blanks the sensitivity towards meropenem (measured in terms of the reduction 
of the MIC values) is enhanced ~20-fold for IMP-1- and AIM-1-producing cells and over 40-
fold for the CphA-expressing strain. 
 
Table 6. MIC values (µg/mL) for meropenem, measured in the absence (Blank) and presence 
of compounds 5a, 8b, 10 or 11. Data were measured for E. coli BL21  expressing either IMP-
1, CphA or AIM-1. 
E. coli BL21 
expressing 
MBL 
MICs of 
meropenem 
without 
inhibitor 
(µg/mL) 
MICs of meropenem measured in the presence of 
inhibitor (µg/mL) 
5a 8b 10 11 
IMP-1 1 0.5 0.047 0.25 0.5 
CphA 1 0.047 0.023 0.75 0.75 
AIM-1 2 0.25 0.094 0.5 0.75 
The inhibitors were used in the concentration of 30 µM. 
 
 
4. Conclusion 
Pyrrole 5a is a broad spectrum inhibitor of members of all three subclasses of MBLs, 
although its mode of action varies from exclusively competitive (IMP-1) to mixed mode of 
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inhibition (CphA and AIM-1). SAR studies show that the N-benzyl group is optimal for 
activity. Removal of this group altogether, or increasing or decreasing the distance between 
the nitrogen atom and the phenyl group decreases potency. The 4,5-geminal diphenyl groups 
may be replaced with furans with no significant loss of activity, but replacement with methyl 
groups leads to almost complete loss of activity. Derivatisation of the nitrile group of 5a to a 
tetrazole led to a substantial loss of activity, and hydrolysis of the nitrile group to the primary 
amide resulted in complete loss of activity. Benzoylation of 5a gave inhibitor 8b, which is 
also a broad spectrum MBL inhibitor, more potent than 5a. Importantly, 8b also significantly 
enhances the sensitivity of cell cultures expressing representatives from the three major 
subgroups of MBLs between 20- to 40-fold. The 4-nitrobenzoyl inhibitor 10 is a potent 
competitive inhibitor of IMP-1 and shows mixed mode inhibition against AIM-1. It is, 
however, inactive towards CphA. The 4-(benzoyl)benzoyl derivative 11 is also a potent 
inhibitor of IMP-1, although now in a purely uncompetitive mode. It is only weakly active 
against CphA, and not at all active against AIM-1. 
The enzyme inhibition and SAR data described in this study should aid in the development of 
compounds that are more potent and active against all three subclasses of MBLs. In particular 
compound 8b has emerged as a promising universal lead for MBL inhibitors. Further studies 
will focus on investigating the inhibitory effects of other substituents on the 3-amino group of 
5a, and visualising the binding mode(s) of the 5a and 8b as they may provide insight into 
sites remote from the metal binding centre that are effective for the development of universal 
MBL inhibitors. Further studies will focus on diminishing the lipophilicity of these 
compounds, investigating the inhibitory effects of other substituents on the 3-amino group of 
5a, and visualising the binding mode(s) of the 5a and 8b as they may provide insight into 
sites remote from the metal binding centre that are effective for the development of universal 
MBL inhibitors. 
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5. Experimental 
5.1. General experimental 
Thionyl chloride and petroleum ether, PE (b.p. 40-60 °C) were distilled before use. Other 
chemicals and reagents were used without prior purification. NMR spectra were recorded on 
Bruker AVANCE 500 or 400 MHz spectrometers. Chemical shifts are reported in parts per 
million (ppm) on a scale relative to the solvent peak CDCl3 (1H, 7.24 ppm; 13C, 77.0 ppm) 
and DMSO-d6 (1H, 2.49 ppm; 13C, 39.5 ppm). Coupling constants (J) are reported in Hz and 
peak multiplicities described as singlet (s), doublet (d), triplet (t), doublet of doublets (dd), 
quintet (quin), triplet of triplets (tt), multiplet (m), or broad (br). Low-resolution ESI-MS 
measurements were carried out on a Bruker Esquire HCT (High Capacity 3D ion trap) 
instrument with a Bruker ESI source. High-resolution electrospray ionisation accurate mass 
measurements (HRMS) were recorded on a Bruker MicrOTOF-Q (quadrupole–Time of 
Flight) instrument with a Bruker ESI source. Accurate mass measurements were carried out 
with external calibration using sodium formate as reference calibrant. Low resolution and 
accurate mass EI were carried out on a Finnigan MAT 900XL Trap instrument at 70eV 
ionising energy. Accurate mass samples were carried out at 5000 Resolving Power as electric 
sector scan measurements using high boiling PFK (perfluorokerosene) as the reference 
material. Infrared (IR) spectroscopy samples were analysed as neat on a Perkin Elmer 
Frontier FT-IR/NIR Spectrometer. 
 
5.2. 2-Amino-1-benzyl-4,5-diphenyl-1H-pyrrole-3-carbonitrile (5a) [33, 50] 
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A mixture of benzoin 2a (4.2 g, 20 mmol), benzylamine 3a (2.1 mL, 2.1 g, 20 mmol) and 
trichloroacetic acid, TCA (0.17 g, 1.0 mmol) in dry toluene (20 mL) was heated under reflux 
using a Dean-Stark apparatus for 2 h. A yellow solution was obtained. Malononitrile (0.66 g, 
10 mmol) was then added to the reaction mixture, followed by 3 drops of pyridine. The 
mixture was further heated under reflux under argon for 17 h. A colour change from yellow 
to olive green and finally dark brown was observed. The excess solvent was removed in 
vacuo to give a brown semi solid residue (7.33 g). The residue was purified by silica gel 
column chromatography [EtOAc/PE (2:23) → EtOAc/PE (7:43)], followed by 
recrystallisation from diethyl ether to afford the title compound 5a as a light brown solid 
(4.67 g, 67%), m.p.:173.5-175.9 °C (lit.[34] m.p.: 173-175 °C). Rf: 0.42 (30% EtOAc in PE, 
visible as a blue spot under UV light). 1H NMR (500 MHz, CDCl3) δ (ppm): 3.85 (br s, 2H, 
NH2, D2O exchangeable), 4.90 (s, 2H, NCH2Ph), 7.06-7.08 (m, 2H, Ar-H), 7.13-7.15 (m, 3H, 
Ar-H), 7.18-7.32 (m, 8H, Ar-H), 7.35-7.38 (m, 2H, Ar-H). 13C NMR (125 MHz, CDCl3) δ 
(ppm): 47.0 (NCH2Ph), 75.9 (C-CN), 117.5 (C≡N), 121.0 (Ar-C), 125.65 (Ar-C), 125.63 
(Ar-C), 126.4 (Ar-CH), 128.0 (Ar-CH), 128.1 (Ar-CH), 128.2 (Ar-CH), 128.67 (Ar-CH), 
128.72 (Ar-CH), 129.3 (Ar-CH), 130.8 (Ar-CH), 131.0 (Ar-CH), 133.2 (Ar-C), 136.1 (Ar-
C), 145.9 (C-NH2). ESI-MS: m/z 350.1 [M + H]+. IR νmax (cm-1): 3406.0 (N-H stretch), 
3333.0 (N-H stretch), 2199.7 (C≡N stretch), 1624.5, 1601.7, 1541.8, 1496.8, 1470.9, 1438.1, 
1365.4, 1339.3. 1H NMR and ESI-MS data are in agreement with the literature [33].  
 
5.3. 2-Amino-1-benzyl-4,5-dimethyl-1H-pyrrole-3-carbonitrile 5b 
Acetoin 2b (0.88 g, 10 mmol) and benzylamine 3a (1.1 mL, 1.1 g, 10 mmol) were used for 
the synthesis of the title compound 5b, which was obtained as a dark brown solid after silica 
gel column chromatography of the crude product [EtOAc/PE (1:4) → EtOAc/PE (3:7)] (2.3 
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g, 61%), m.p.: 110.3-115.9 °C. Rf: 0.52 (30% EtOAc in PE, visible as a blue spot under 254 
nm). 1H NMR (400 MHz, CDCl3) δ (ppm): 1.99 (d, 3H, J = 0.5 Hz, CH3), 2.03 (d, 3H, J = 
0.6 Hz, CH3), 3.59 (br s, 2H, NH2, exchangeable with D2O), 4.90 (s, 2H, NCH2Ph), 6.96-
6.99 (m, 2H, Ar-H), 7.26-7.34 (m, 3H, Ar-H). 13C NMR (100 MHz, CDCl3) δ (ppm): 9.5 
(CCH3), 10.0 (CCH3), 45.9 (NCH2Ph), 113.5 (C), 117.7 (C≡N), 119.2 (C), 125.7 (Ar-CH), 
127.8 (Ar-CH), 129.1 (Ar-CH), 136.3 (Ar-C) 143.2 (C-NH2); LRMS: m/z 248.1 [M + Na]+. 
IR νmax (cm-1): 3418.5 (N-H stretch), 3330.8 (N-H stretch), 3233.3, 2202.1 (C≡N stretch), 
1650.9, 1603.3, 1564.2, 1509.2, 1496.2, 1455.0, 1441.9, 1354.6, 1303.7, 1244.4, 1176.6, 
1146.9, 1016.4.  
 
5.4. 2-Amino-1-benzyl-4,5-di(furan-2-yl)-1H-pyrrole-3-carbonitrile (5c) 
Furoin 2c (1.92 g, 10.0 mmol) and benzylamine 3a (1.1 mL, 1.1 g, 10 mmol) were used for 
the synthesis of the title compound 5c, which was obtained as a dark brown solid after silica 
gel column chromatography of the crude product [EtOAc/PE (1:4) → EtOAc/PE (3:7)] (1.9 
g, 59%), m.p.: 138.0-145.8 °C. Rf: 0.54 (30% EtOAc in PE, visible as a blue spot under UV 
light). 1H NMR (400 MHz, CDCl3) δ (ppm): 3.91 (br s, 2H, NH2, D2O exchangeable), 4.88 
(s, 2H, NCH2Ph), 6.34 (d, 2H, J = 1.2 Hz, furanyl-H), 6.43-6.46 (m, 2H, furanyl-H), 7.09-
7.11 (m, 2H, Ar-H), 7.35-7.36 (m, 4H, Ar-H), 7.47 (dd, 1H, J1 = 0.8 Hz, J2 = 1.8 Hz, Ar-H). 
13C NMR (100 MHz, CDCl3) δ (ppm): 47.4 (NCH2Ph), 74.1 (C-CN), 106.6 (Ar-CH), 111.0 
(Ar-CH), 111.1 (C), 113.1 (Ar-CH), 114.2 (Ar-C), 115.2 (C), 116.7 (C≡N), 126.3 (Ar-CH), 
128.2 (Ar-CH), 129.2 (Ar-CH), 135.5 (C) 141.4 (Ar-CH), 143.3 (Ar-CH), 143.5 (C), 146.4 
(C-NH2), 147.3 (C); LRMS: m/z 328.1 [M + H]-. IR νmax (cm-1): 3454.2 (N-H stretch), 
3327.5 (N-H stretch), 3269.0, 3236.6, 3210.6, 3152.1, 3116.4, 2200.1 (C≡N stretch), 1673.7, 
1633.9, 1562.7, 1497.0, 1456.0, 1346.0, 1203.0, 1156.9, 1013.0. 
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5.5. 2-Amino-1-(4-methoxybenzyl)-4,5-diphenyl-1H-pyrrole-3-carbonitrile 5d 
Benzoin 2a (2.12 g, 10.0 mmol) and 4-methoxybenzylamine 3b (1.3 mL, 1.4 g, 10 mmol) 
were used for the synthesis of the title pyrrole 5d, which was obtained as a golden solid (2.4 
g, 63%), m.p.: 148.0-150.6 °C. Rf: 0.40 (30% EtOAc in PE, visible as a blue spot under UV 
light). 1H NMR (400 MHz, CDCl3) δ (ppm): 3.79 (s, 3H, OCH3), 3.88 (br s, 2H, NH2, D2O 
exchangeable), 4.84 (s, 2H, NCH2PhOCH3), 6.88 (d, 2H, J = 8.8 Hz, Ar-H), 6.99 (d, 2H, J = 
8.8 Hz, Ar-H), 7.14-7.27 (m, 10H, Ar-H). 13C NMR (100 MHz, CDCl3) δ (ppm): 46.5 
(NCH2PhOCH3), 55.3 (OCH3), 75.7 (C-C≡N), 114.7 (Ar-CH), 117.5 (C≡N), 120.9 (Ar-C), 
125.3 (Ar-CH), 125.6 (Ar-C), 126.4 (Ar-CH), 127.2 (Ar-CH), 127.8 (Ar-C), 128.1 (Ar-CH), 
128.2 (Ar-CH), 128.68 (Ar-CH), 128.72 (Ar-CH), 129.0 (Ar-CH), 130.9 (Ar-C) 131.0 (Ar-
CH), 133.2 (Ar-C), 137.8 (Ar-C), 145.9 (Ar-C), 159.3 (Ar-C); LRMS: m/z 378.2 [M - H]-. 
HRMS, found: m/z 378.1599, C25H20N3O requires 378.1612. IR νmax (cm-1): 3416.3 (N-H 
stretch), 3328.3 (N-H stretch), 3233.7, 2202.9 (C≡N stretch), 1651.5, 1603.3, 1564.4, 1508.8, 
1495.9, 1455.4, 1441.9, 1354.6, 1244.0, 1176.6, 1016.5.  
 
5.6. 2-Amino-1-phenethyl-4,5-diphenyl-1H-pyrrole-3-carbonitrile (5e) 
Benzoin 2a (2.12 g, 10.0 mmol) and phenethylamine 3c (1.3 mL, 1.2 g, 10 mmol) were used 
for the synthesis of the title compound. Silica gel column chromatography [EtOAc/PE (1:9) 
→ EtOAc/PE (23:77)] of the crude product afforded the title pyrrole 5e as a brown solid (2.8 
g, 78%), m.p.: 186.2-190.7 oC. Rf: 0.33 (30% EtOAc in PE, visible as a blue spot under UV 
light). 1H NMR (400 MHz, CDCl3) δ (ppm): 2.71 (t, 2H, J = 7.0 Hz, CH2Ph), 3.46 (br s, 2H, 
NH2, D2O exchangeable), 3.90 (t, 2H, J = 7.0 Hz, NCH2), 6.91-6.93 (m, 2H, Ar-H), 7.11-
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
24 
 
7.25 (m, 10H, Ar-H), 7.34-7.36 (m, 3H, Ar-H). 13C NMR (100 MHz, CDCl3) δ (ppm): 36.2 
(CH2), 45.0 (N-CH2), 76.1 (C-CN), 117.7 (C≡N), 121.1 (Ar-C), 125.2 (Ar-C), 126.3 (Ar-
CH), 127.1 (Ar-CH), 128.1 (Ar-CH), 128.3 (Ar-CH), 128.5 (Ar-CH), 128.7 (Ar-CH), 128.8 
(Ar-CH), 128.9 (Ar-CH), 131.5 (Ar-CH), 133.1 (Ar-C), 137.6 (Ar-C), 145.5 (Ar-C); LRMS: 
m/z 362.0 [M - H]-. HRMS, found: m/z 362.1663, C25H20N3 requires 362.1663. IR νmax (cm-
1): 3428.2 (N-H stretch), 3349.0 (N-H stretch), 3059.0, 3025.8, 2937.0, 2194.5 (C≡N stretch), 
1624.0, 1601.2, 1545.9, 1496.9, 1481.7, 1453.8, 1442.1, 1350.8, 1224.0, 1141.2, 1029.5, 
1013.7. 
 
 
5.7. 2-Amino-4,5-diphenyl-1-(3-phenylpropyl)-1H-pyrrole-3-carbonitrile 5f 
Benzoin 2a (2.12 g, 10.0 mmol) and 3-phenyl-1-propylamine 3d (1.4 mL, 1.4 g, 10 mmol) 
were used for the synthesis of the title compound. Filtration of the reaction mixture and 
washing of the precipitate with cold toluene (2 x 30 mL) afforded the pyrrole 5f as a light 
brown solid (2.0 g, 53%), m.p.: 159.7-169.0 oC. Rf: 0.38 (30% EtOAc in PE, visible as a blue 
spot under UV light). 1H NMR (400 MHz, CDCl3) δ (ppm): 1.85 (quin, 2H, J = 7.6 Hz, 
CH2CH2Ph),  2.46 (t, 2H, J = 7.4 Hz, CH2Ph), 3.65 (t, 2H, J = 7.8 Hz, NCH2), 7.00-7.02 (m, 
2H, Ar-H), 7.09-7.26 (m, 10H, Ar-H), 7.30-7.39 (m, 3H, Ar-H). 13C NMR (100 MHz, 
CDCl3) δ (ppm): 30.7 (CH2), 32.5 (CH2), 42.6 (N-CH2), 75.7 (C-CN), 117.7 (C≡N), 120.9 
(Ar-C), 125.3 (Ar-C), 126.3 (Ar-CH), 128.09 (Ar-CH), 128.13 (Ar-CH), 128.56 (Ar-CH), 
128.59 (Ar-CH), 128.7 (Ar-CH), 128.91 (Ar-CH), 128.94 (Ar-CH), 131.2 (Ar-CH), 133.1 
(Ar-C), 140.2 (Ar-C), 145.2 (Ar-C); LRMS: m/z 376.1 [M - H]-. HRMS, found: m/z 
376.1815, C26H22N3 requires 376.1819. IR νmax (cm-1): 3420.0 (N-H stretch), 3338.3 (N-H 
stretch), 3243.6, 3059.3, 3024.3, 2934.1, 2856.0, 2191.5 (C≡N stretch), 1947.4, 1632.5, 
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1601.3, 1558.4, 1505.4, 1495.3, 1462.9, 1453.1, 1444.1, 1372.4, 1356.8, 1320.3, 1227.9, 
1211.7, 1179.3, 1151.3, 1110.2, 1079.8, 1029.4. 
 
5.8. 2-Amino-4,5-diphenyl-1-(4-phenylbutyl)-1H-pyrrole-3-carbonitrile 5g 
Benzoin 2a (2.12 g, 10.0 mmol) and 4-phenylbutylamine 3e (1.6 mL, 1.5 g, 10 mmol) were 
used for the synthesis of the title compound. Silica gel column chromatography [EtOAc/PE 
(1:4) → EtOAc/PE (23:77)] of the crude product afforded the pyrrole 5g as a brown solid 
(2.8 g, 78%), m.p.: 150.3-153.1oC. Rf: 0.40 (30% EtOAc in PE, visible as a blue spot under 
UV light). 1H NMR (400 MHz, CDCl3) δ (ppm): 1.42-1.57 (m, 4H 2 x CH2), 2.47 (t, 2H, J = 
7.3 Hz, CH2Ph), 3.64 (t, 2H, J = 7.0 Hz, NCH2), 7.02-7.05 (m, 2H, Ar-H), 7.16-7.26 (m, 
10H, Ar-H), 7.30-7.31 (m, 3H, Ar-H). 13C NMR (100 MHz, CDCl3) δ (ppm): 27.8 (CH2), 
28.9 (CH2), 34.9 (CH2), 43.2 (N-CH2), 75.8 (C-CN), 117.7 (C≡N), 120.9 (Ar-C), 125.2 (Ar-
C), 126.0 (Ar-CH), 126.2 (Ar-CH), 128.08 (Ar-CH), 128.12 (Ar-CH), 128.3 (Ar-CH), 128.4 
(Ar-CH), 128.59 (Ar-CH), 128.64 (Ar-CH), 131.3 (Ar-CH), 133.2 (Ar-C), 141.3 (Ar-C), 
145.1 (Ar-C); LRMS: m/z 390.1 [M - H]-. HRMS, found: m/z 390.1970, C27H24N3 requires 
390.1976. IR νmax (cm-1): 3418.6 (N-H stretch), 3341.1 (N-H stretch), 3243.8, 3061.6, 3024.6, 
2934.2, 2857.4, 2191.2 (C≡N stretch), 1947.6, 1631.6, 1601.0, 1558.2, 1495.4, 1462.7, 
1453.2, 1443.5, 1357.3, 1319.7, 1225.9, 1212.0, 1179.6, 1150.0, 1110.5, 1074.7, 1029.3, 
733.5. 
 
5.9. 2-Amino-1,4,5-triphenyl-1H-pyrrole-3-carbonitrile 5h [34] 
Malononitrile (0.18 g, 2.7 mmol) was added to a hot solution of α–aminoketone 6 (0.78 g, 2.7 
mmol) in absolute EtOH (6 mL). A solution of sodium (72 mg, 3.1 mmol) in absolute EtOH 
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(3 mL) was then added dropwise to the mixture, and the mixture was heated under reflux for 
18 h. The orange solid which formed was filtered off and washed with EtOH (2 x 10 mL). 
Recrystallisation from MeOH afforded the pyrrole 5h as an orange solid (0.55 g, 60%), m.p.: 
242.7-247.0°C (lit. [34] m.p. 248-250°C). 1H NMR (400 MHz, CDCl3) δ (ppm): 4.15 (br s, 
2H, NH2), 6.87-6.90 (m, 2H, Ar-H), 7.02-7.08 (m, 3H, Ar-H), 7.13-7.29 (m, 7H, Ar-H), 
7.33-7.39 (m, 3H, Ar-H). 13C NMR (100 MHz, CDCl3) δ (ppm): 74.2 (C-CN), 117.4 (C≡N), 
121.3 (Ar-C), 124.7 (Ar-C), 126.6 (Ar-CH), 127.0 (Ar-CH), 128.0 (Ar-CH), 128.2 (Ar-CH), 
128.3 (Ar-CH), 128.8 (Ar-CH), 129.0 (Ar-CH), 129.7 (Ar-C), 130.6 (Ar-C), 130.7 (Ar-CH), 
133.1 (Ar-C), 135.3 (Ar-C), 146.5 (C-NH2); LRMS: m/z 358.0 [M + Na]+. HRMS, found: 
m/z 358.1316, C23H17N3Na requires 358.1315. IR (νmax, cm-1): 3473.5 (N-H stretch), 3384.4 
(N-H stretch), 3221.5, 3053.5, 2199.6 (C≡N stretch), 1614.2, 1596.0, 1559.0, 1548.2, 1494.1, 
1474.2, 1453.6, 1439.3, 1355.6, 1268.9, 1221.5, 1154.2. 
 
5.10. 1,2-Diphenyl-2-(phenylamino)ethanone 6 
A mixture of benzoin 2a (2.12 g, 10.0 mmol), aniline 3f (1.0 mL, 1.1 g, 10 mmol) and 
trichloroacetic acid (0.08 g, 0.5 mmol) in dry toluene (20 mL) was refluxed using a Dean-
Stark apparatus for 3 h (LRMS monitoring). The yellow solution was evaporated in vacuo to 
give a brown solid residue (3.3 g). Silica gel column chromatography [EtOAc/PE (1:19) → 
EtOAc/PE (7:93)] afforded the α–aminoketone 6 as a brown solid (1.81 g, 63%), m.p.: 93.8-
95.7 °C (lit. [51] m.p. 98-99 °C). Rf: 0.58 (30% EtOAc in PE). 1H NMR (300 MHz, CDCl3) δ 
(ppm): 6.03 (s, 1H, CHNH), 6.68-6.71 (m, 3H, Ar-H), 7.09-7.29 (m, 5H, Ar-H), 7.39-7.44 
(m, 4H, Ar-H), 7.52 (tt, 1H, J1 = 2.4 Hz, J2 = 7.5 Hz), 7.95-7.98 (m, 2H, Ar-H). 13C NMR 
(75 MHz, CDCl3) δ (ppm): 63.3 (CHNH), 114.3 (Ar-CH), 118.6 (Ar-C), 128.2 (Ar-CH), 
128.3 (Ar-CH), 128.7 (Ar-CH), 128.9 (Ar-CH), 129.1 (Ar-CH), 129.2 (Ar-CH), 133.5 (Ar-
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CH), 134.9 (Ar-CH), 137.1 (Ar-C), 145.2 (Ar-C), 196.7 (C=O); LRMS: m/z 288.0 [M + H]+. 
IR νmax (cm-1): 3408.8 (N-H stretch), 3386.2, 3050.3, 1679.3 (C=O stretch), 1596.4, 1579.1, 
1502.6, 1447.3, 1427.6, 1320.3, 1246.0, 1173.7. 
 
5.11. General procedure for the preparation of acyl chlorides [52] 
A mixture of thionyl chloride (2.0 mL, 3.6 g, 30 mmol) and the corresponding carboxylic 
acid (3 mmol) was refluxed for 1.5 h. Excess thionyl chloride was removed by distillation. 
The residue obtained was co-evaporated with toluene (3 x 5 mL) in vacuo to ensure the 
complete removal of thionyl chloride. The acyl chloride product was used without further 
purification in the next step. 
 
5.12. General procedure for the condensation of pyrrole 5a with acyl chlorides 
A solution of the appropriate acyl chloride (2.4 mmol) in toluene (2.0 mL) was added 
dropwise to a stirred mixture of pyrrole 5a (0.21 g, 0.60 mmol) and triethylamine (0.50 mL, 
0.36 g, 3.6 mmol) in dry toluene (8 mL). The reaction mixture was refluxed overnight under 
argon. The excess solvent was removed in vacuo and the residue obtained was dissolved in 
EtOAc (20 mL) and washed successively with 5% HCl (10 mL), saturated NaHCO3 (10 mL) 
and brine (10 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The 
crude product was purified by silica gel column chromatography. 
 
5.13. General procedure for the partial deacylation of N,N-diacyl imides 7 to N-acyl amides 
8 
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Equimolar quantities of potassium carbonate (28 mg, 0.20 mmol) and the appropriate N,N-
diacyl imide 7 (0.20 mmol) were stirred at room temperature for 1 h in either MeOH or 
acetone/MeOH (1:1) (2.5 mL). The excess solvent was removed in vacuo and the residue was 
dissolved in CHCl3 (15 mL) and partitioned with water (15 mL). The aqueous layer was 
extracted with CHCl3 (2 x 5 mL). The organic layers were combined, washed with brine (20 
mL), dried over Na2SO4 and concentrated in vacuo. The crude product 8 was purified by 
recrystallisation or silica gel column chromatography. 
 
5.14. N-Acetyl-N-(1-benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)acetamide 7a 
A mixture of pyrrole 5a (0.20 g, 0.58 mmol) and acetic anhydride (2.3 mL, 2.5 g, 24 mmol) 
was heated under reflux for 3 h under argon. The reaction mixture was allowed to cool and 
then poured into a mixture of ice and water. Ammonia (25%, 10 mL) was added to the 
mixture until a red precipitate was formed. The precipitate was vacuum-filtered and 
recrystallised from diethyl ether to afford the title compound 7a as a brown solid (0.20 g, 
79%), m.p.: 173.0-177.8 °C. Rf: 0.45 (30% EtOAc in PE). 1H NMR (300 MHz, CDCl3) δ 
(ppm): 2.15 (s, 6H, 2 x COCH3), 4.85 (s, 2H, NCH2Ph), 6.95-6.99 (m, 2H, Ar-H), 7.22-7.38 
(m, 13H, Ar-H). 13C NMR (75 MHz, CDCl3) δ (ppm): 25.6 (COCH3), 48.6 (NCH2Ph), 92.5 
(C-CN), 114.4 (C≡N), 124.2 (Ar-C), 127.1 (Ar-CH), 127.5 (Ar-CH), 128.3 (Ar-CH), 128.4 
(Ar-CH), 128.8 (Ar-CH), 129.95 (Ar-CH), 129.01 (Ar-CH), 129.1 (Ar-CH), 130.0 (Ar-C), 
131.4 (Ar-CH), 131.8 (Ar-C), 133.6 (Ar-C), 135.2 (C-NH2), 172.1 (C=O). ESI-MS: m/z 
456.2 [M + Na]+. HRMS, found: m/z 456.1683, C28H23N3NaO2 requires 456.1682. IR νmax 
(cm-1): 3033.8, 2223.8 (C≡N stretch), 1743.3 (C=O stretch), 1705.0 (C=O stretch), 1605.2, 
1533.7, 1497.2, 1479.3, 1455.9, 1446.4, 1429.1, 1364.1, 1349.7, 1255.8, 1202.2, 1016.6. 
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5.15. N-Benzoyl-N-(1-benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)benzamide 7b 
Benzoyl chloride (0.28 mL, 0.34 g, 2.4 mmol) was used. The crude product was purified by 
silica gel chromatography [EtOAc/PE (3:97) → EtOAc/PE (3:22)] to afford 7b as a light 
brown solid (0.25 g, 76%), m.p.: 181.9-184.4 °C. Rf: 0.56 (30% EtOAc in PE). 1H NMR (300 
MHz, CDCl3) δ (ppm): 5.05 (s, 2H, NCH2Ph), 6.84-6.87 (m, 2H, Ar-H), 7.00-7.03 (m, 2H, 
Ar-H), 7.09-7.26 (m, 15H, Ar-H), 7.37 (tt, 2H, J1 = 7.5 Hz, J2 = 1.5 Hz, Ar-H), 7.58-7.61 (m, 
4H, Ar-H). 13C NMR (75 MHz, CDCl3) δ (ppm): 48.5 (NCH2Ph), 93.0 (C-CN), 115.2 
(C≡N), 124.5, 126.4, 127.0, 127.5, 128.3, 128.5, 128.6, 128.7, 128.9, 129.1, 130.1, 131.0, 
131.5, 132.0, 132.8, 133.6, 133.8, 134.0, 135.4 (C-NH2), 172.10 (C=O). ESI-MS: m/z 580.2 
[M + Na]+. HRMS, found: m/z 580.1979, C38H27N3NaO2 requires 580.1995. IR νmax (cm-1): 
3063.1, 3031.6, 2222.8 (C≡N stretch), 1713.0 (C=O stretch), 1677.5 (C=O stretch), 1596.3, 
1580.6, 1564.8, 1532.9, 1497.3, 1476.5, 1463.8, 1448.9, 1424.5, 1316.1, 1223.1, 1120.4, 
1073.3, 1065.1, 1073.3. 
 
5.16. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)-N-butyrylbutyramide 7c 
Butyryl chloride (0.25 mL, 0.26 g, 2.4 mmol) was used. The crude product was purified by 
silica gel chromatography [ tOAc/PE (1:49) → EtOAc/PE (1:19)] to afford 7c as a light 
brown solid (0.25 g, 86%), m.p.: 114.6-115.2 °C. Rf: 0.73 (30% EtOAc in PE). 1H NMR (400 
MHz, CDCl3) δ (ppm): 0.91 (t, 6H, J = 7.4 Hz, 2 x CH3), 1.40-1.53 (m, 2H, CH2CH3), 1.56-
1.69 (m, 2H, CH2CH3), 2.20-2.28 (m, 2H, COCH2), 2.60-2.68 (m, 2H, COCH2), 4.88 (s, 2H, 
NCH2Ph), 6.98-7.01 (m, 2H, Ar-H), 7.22-7.28 (m, 8H, Ar-H), 7.34-7.42 (m, 5H, Ar-H). 13C 
NMR (100 MHz, CDCl3) δ (ppm): 13.5 (CH3), 17.8 (CH2CH3), 39.5 (COCH2), 48.4 
(NCH2Ph), 92.6 (C-CN), 114.6 (C≡N), 124.2 (Ar-C), 127.1 (Ar-CH), 127.5 (Ar-CH), 
128.29 (Ar-CH), 128.32 (Ar-CH), 128.9 (Ar-CH), 129.0 (Ar-CH), 129.1 (Ar-CH), 130.2 
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(Ar-C), 131.4 (Ar-C), 131.5 (Ar-CH), 131.9 (Ar-C), 133.4 (Ar-C), 135.2 (C-NH2), 175.1 
(C=O). ESI-MS: m/z 512.2 [M + Na]+. HRMS, found: m/z 512.2309, C32H31N3NaO2 requires 
512.2308. IR νmax (cm-1): 3056.8, 3031.6, 2920.9 (sp3 C-H stretch), 2850.5 (sp3 C-H stretch), 
2224.0 (C≡N stretch), 1683.3 (C=O stretch), 1602.6, 1564.8, 1531.0, 1497.5, 1466.6, 1450.6, 
1415.9, 1367.7, 1351.6, 1221.7, 1183.4, 1075.8, 1029.2, 709.7. 
 
 
5.17. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)-N-tetradecanoyltetradecanamide 7d 
Myristoyl chloride (0.61 g, 2.5 mmol) was used. The crude product was purified by silica gel 
chromatography [EtOAc/PE (1:49) → EtOAc/PE (1:19)] to afford 7d as a clear golden oil 
(0.43 g, 93%). Rf: 0.90 (30% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ (ppm): 0.86 (t, 
6H, J = 6.0 Hz, 2 x CH3), 1.24 (br s, 44H, CH2CH3 x 22), 2.16-2.24 (m, 2H, COCH2), 2.56-
2.64 (m, 2H, COCH2), 4.83 (s, 2H, NCH2Ph), 6.93-6.95 (m, 2H, Ar-H), 7.19-7.37 (m, 13H, 
Ar-H). 13C NMR (100 MHz, CDCl3) δ (ppm): 14.1 (CH3), 22.7 (CH2), 24.4 (CH2), 29.0 
(CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.61 (CH2), 29.64 (CH2), 29.7 (CH2), 31.9 
(CH2), 37.7 (COCH2), 48.4 (NCH2Ph), 92.6 (C-CN), 114.6 (C≡N), 124.2 (Ar-C), 127.1 (Ar-
CH), 127.5 (Ar-CH), 128.27 (Ar-CH), 128.33 (Ar-CH), 128.9 (Ar-CH), 129.0 (Ar-CH), 
129.1 (Ar-CH), 130.2 (Ar-C), 131.3 (Ar-C), 131.5 (Ar-CH), 132.0 (Ar-C), 133.5 (Ar-C), 
135.2 (C-NH2), 175.3 (C=O). ESI-MS: m/z 792.5 [M + Na]+. HRMS, found: m/z 792.5449, 
C52H71N3NaO2 requires 792.5438. IR νmax (cm-1): 3066.0, 3028.0, 2918.0 (sp3 C-H stretch), 
2849.9 (sp3 C-H stretch), 2221.9 (C≡N stretch), 1677.6 (C=O stretch), 1603.0, 1562.7, 
1497.6, 1465.3, 1453.7, 1422.5, 1354.0, 1301.0, 1275.3, 1223.8, 1180.5, 1074.4, 1022.4, 
727.5. 
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5.18. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)acetamide 8a 
Potassium carbonate (21 mg, 0.15 mmol) and imide 7a (65 mg, 0.15 mmol) were used. 
MeOH (6 mL) was used as the solvent. The crude product was recrystallised from diethyl 
ether to afford 8a as a peach-coloured solid (40 mg, 68%). Rf: 0.14 (30% EtOAc in PE). Mp: 
130.2-132.6 °C. 1H NMR (400 MHz, CDCl3) δ (ppm): 2.05 (s, 3H, COCH3), 4.97 (s, 2H, 
NCH2Ph), 6.84-6.86 (m, 2H, Ar-H), 7.14-7.27 (m, 13H, Ar-H), 7.67 (br s, 1H NH). 13C 
NMR (100 MHz, CDCl3) δ (ppm): 29.7 (COCH3), 48.5 (NCH2Ph), 89.8 (C-CN), 115.7 
(C≡N), 123.4 (Ar-C), 126.0 (Ar-CH), 126.8 (Ar-CH), 127.7 (Ar-CH), 128.3 (Ar-CH), 128.7 
(Ar-CH), 128.9 (Ar-CH), 130.2 (Ar-C), 130.4 (Ar-C), 131.2 (Ar-CH), 132.4 (Ar-C), 132.7 
(Ar-C), 136.8 (C-NH2), 170.1 (C=O). ESI-MS: m/z 414.2 [M + Na]+. HRMS, found: m/z 
414.1573, C26H21N3NaO requires 414.1577. IR νmax (cm-1): 3236.6 (N-H stretch), 3063.1, 
3031.6, 2222.2 (C≡N stretch), 1675.2 (C=O stretch), 1583.2, 1564.1, 1541.8, 1497.3, 1452.7, 
1423.7, 1366.9, 1355.2, 1332.4, 1296.3, 1260.5, 1075.4, 1020.1, 1003.7. 
 
5.19. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)benzamide 8b 
Potassium carbonate (28 mg, 0.20 mmol) and imide 7b (0.11 g, 0.20 mmol) were used. A 1:1 
mixture of acetone/MeOH (12 mL) was used as the solvent. The title compound 8b was 
obtained as a white solid after recrystallisation of the crude product from MeOH (48 mg, 
53%), m.p.: 196.8-202.4 °C. Rf: 0.51 (30% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 
(ppm): 5.05 (s, 2H, Ar-CH2), 6.86-6.88 (m, 2H, Ar-H), 7.16-7.40 (m, 15H, Ar-H), 7.51 (tt, 
1H, J1 = 7.5 Hz, J2 = 1.4 Hz, Ar-H), 7.61-7.64 (m, 2H, Ar-H), 7.81 (br s, 1H, NH). 13C NMR 
(100 MHz, CDCl3) δ (ppm): 48.7 (NCH2Ph), 89.9 (C-CN), 115.8 (C≡N), 123.5, 126.1, 
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126.8, 127.5, 127.7, 128.3, 128.69, 128.74, 128.95, 128.96, 130.3, 130.6, 131.2, 132.4, 132.6, 
132.77, 136.8 (C-NH2), 166.9 (C=O). ESI-MS: m/z 452.1 [M - H]-. HRMS, found: m/z 
452.1762, C31H22N3O requires 452.1768. IR νmax (cm-1): 3249.2 (N-H stretch), 3063.1, 
3031.6, 2221.9 (C≡N stretch), 1678.0 (C=O stretch), 1581.0, 1555.6, 1532.7, 1498.1, 1479.2, 
1448.5, 1422.9, 1353.4, 1314.4, 1275.4, 1222.9, 1180.3, 1120.1, 1073.9, 1022.1. 
 
 
 
5.20. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)butyramide 8c 
Potassium carbonate (28 mg, 0.20 mmol) and imide 7c (0.10 g, 0.20 mmol) were used. 
MeOH (12 mL) was used as the solvent. The crude product was purified by recrystallisation 
from MeOH to afford 8c as a light yellow solid (80 mg, 95%), m.p.: 201.0-203.0 °C. Rf: 0.50 
(30% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ (ppm): 0.94 (t, 3H, J = 7.4 Hz, CH3), 
1.63-1.68 (m, 2H, CH2CH3), 2.25 (t, 2H, J = 7.4 Hz, COCH2), 4.98 (s, 2H, NCH2Ph), 6.84-
6.86 (m, 2H, Ar-H), 7.10-7.27 (m, 13H, Ar-H). 13C NMR (100 MHz, CDCl3) δ (ppm): 13.6 
(CH3), 18.9 (CH2CH3), 38.0 (COCH2), 48.4 (NCH2Ph), 89.7 (C-CN), 115.7 (C≡N), 123.4 
(Ar-C), 125.9 (Ar-CH), 126.8 (Ar-CH), 127.6 (Ar-CH), 128.2 (Ar-CH), 128.6 (Ar-CH), 
128.7 (Ar-CH), 128.85 (Ar-CH), 128.91 (Ar-CH), 130.29 (Ar-C), 130.34 (Ar-C), 131.1 (Ar-
CH), 132.4 (Ar-C), 132.9 (Ar-C), 136.8 (C-NH2), 173.1 (C=O). ESI-MS: m/z 418.1 [M - H]-
. HRMS, found: m/z 418.1923, C28H24N3O requires 418.1925. IR νmax (cm-1): 3236.6 (N-H 
stretch), 3053.7, 3034.7, 2920.8 (sp3 C-H stretch), 2850.5 (sp3 C-H stretch), 2224.1 (C≡N 
stretch), 1683.1 (C=O stretch), 1605.8, 1561.6, 1530.6, 1497.5, 1466.7, 1450.3, 1415.4, 
1367.9, 1351.6, 1221.1, 1076.0, 1029.2, 709.9. 
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5.21. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)tetradecanamide 8d 
Potassium carbonate (37 mg, 0.27 mmol) and imide 7d (0.21 g, 0.27 mmol) were used. A 1:1 
mixture of AcMe/MeOH (12 mL) was used as the solvent. Silica gel column chromatography 
[EtOAc/PE (1:49) → EtOAc/PE (7:93)] of the crude product afforded 8d as a light yellow 
solid (0.13 g, 87%), m.p.: 125.4-126.6 °C. Rf: 0.80 (30% EtOAc in PE). 1H NMR (400 MHz, 
CDCl3) δ (ppm): 0.86 (t, 3H, J = 6.9 Hz, CH3), 1.24 (s, 20H, 10 x CH2CH3), 1.56-1.59 (m, 
2H, COCH2CH2), 2.26 (t, 2H, J = 7.5 Hz, COCH2), 4.98 (s, 2H, NCH2Ph), 6.84-6.86 (m, 2H, 
Ar-H), 6.97 (br s, 1H, NH), 7.14-7.28 (m, 13H, Ar-H). 13C NMR (100 MHz, CDCl3) δ 
(ppm): 14.1 (CH3), 22.7 (CH2), 25.4 (CH2), 29.1 (CH2), 29.28(CH2), 29.33 (CH2), 29.4 
(CH2), 29.59 (CH2), 29.63 (CH2), 29.7 (CH2), 31.9 (CH2), 36.2 (COCH2), 48.4 (NCH2Ph), 
89.7 (C-CN), 115.7 (C≡N), 123.4 (Ar-C), 125.9 (Ar-CH), 126.8 (Ar-CH), 127.6 (Ar-CH), 
128.2 (Ar-CH), 128.6 (Ar-CH), 128.7 (Ar-CH), 128.86 (Ar-CH), 128.91 (Ar-CH), 130.29 
(Ar-C), 130.34 (Ar-C), 131.1 (Ar-CH), 132.4 (Ar-C), 132.9 (Ar-C), 136.8 (C-NH2), 173.2 
(C=O). ESI-MS: m/z 582.4 [M + Na]+. HRMS, found: m/z 582.3460, C38H45N3NaO requires 
582.3455. IR νmax (cm-1): 3239.8 (N-H stretch), 3053.7, 3034.7, 2920.5 (sp3 C-H stretch), 
2850.4 (sp3 C-H stretch), 2224.2 (C≡N stretch), 1683.4 (C=O stretch), 1602.6, 1561.8, 
1529.7, 1497.4, 1467.0, 1450.3, 1415.9, 1367.9, 1351.7, 1221.5, 1076.1, 1029.3, 709.9. 
 
5.22.N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)-4-nitro-N-(4-
nitrobenzoyl)benzamide 9 
4-Nitrobenzoyl chloride (0.46 g, 2.4 mmol) was used. The imide 9 was obtained as an orange 
solid after silica gel column chromatography [EtOAc/PE (1:49) → EtOAc/PE (1:24)] of the 
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crude product (0.12 g, 26%), m.p.: 243.5-245.4 °C. Rf: 0.75 (30% EtOAc in PE). 1H NMR 
(400 MHz, CDCl3) δ (ppm): 5.43 (br s, 2H, NCH2Ph), 6.94-6.96 (m, 2H, Ar-H), 7.10-7.13 
(m, 2H, Ar-H), 7.23-7.36 (m, 11H, Ar-H), 8.08 (d, 2H, J = 9.0 Hz, Ar-H), 8.15 (d, 2H, J = 
9.0 Hz, Ar-H), 8.33 (d, 2H, J = 9.1 Hz, Ar-H), 8.49 (d, 2H, J = 9.0 Hz, Ar-H). ESI-MS: m/z 
648.3 [M + H]+. 13C NMR (100 MHz, CDCl3) δ (ppm): 46.9 (NCH2Ph), 102.0 (C-CN), 120.7 
(C≡N), 123.2 (CH-Ar), 124.1 (CH-Ar), 127.0 (CH-Ar), 127.5 (CH-Ar), 127.9 (CH-Ar), 
128.6 (CH-Ar), 128.8 (CH-Ar), 129.0 (CH-Ar), 129.1 (CH-Ar), 129.4 (C-Ar), 130.8 (CH-
Ar), 131.0 (CH-Ar), 131.2 (CH-Ar), 132.1 (C-Ar), 135.5 (C-Ar), 136.5 (C-Ar), 136.9 (C-
Ar), 141.8 (C-Ar), 144.7 (C-Ar), 149.9 (C-Ar), 152.0 (C-Ar), 155.1 (C-NH2), 172.3 (C=O). 
ESI-MS: m/z 648.3 [M + H]+. HRMS, found: m/z 648.1883, C38H26N5O6 requires 648.1878. 
IR νmax (cm-1): 3113.6, 3060.0, 3034.7, 2224.9 (C≡N stretch), 1699.7 (C=O stretch), 1605.8, 
1518.6 (N-O asymmetric stretch), 1496.1, 1445.9, 1342.0 (N-O symmetric stretch), 1272.3, 
1255.7, 1206.7, 1076.4, 1009.7. 
 
5.23. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)-4-nitrobenzamide 10 
Further elution of the column [EtOAc/PE (1:49) → EtOAc/PE (1:12)] gave the amide 10 as a 
light yellow solid (0.11 g, 36%), m.p.: 214.3-215.4 °C. Rf: 0.51 (30% EtOAc in PE). 1H NMR 
(400 MHz, CDCl3) δ (ppm): 5.02 (br s, 2H, NCH2Ph), 6.85-6.87 (m, 2H, Ar-H), 7.17-7.33 
(m, 13H, Ar-H), 7.70 (d, 2H, J = 8.7 Hz, Ar-H), 8.12 (d, 2H, J = 8.8 Hz, Ar-H), 8.46 (br s, 
1H, NHCO). 13C NMR (100 MHz, CDCl3) δ (ppm): 49.0 (NCH2Ph), 89.6 (C-CN), 116.1 
(C≡N), 123.68, 123.72, 126.0, 127.1, 127.9, 128.3, 128.8, 128.90, 128.9, 129.1, 130.0, 131.1, 
131.2, 132.2, 132.3, 136.4, 137.8, 150.0 (C-NH2), 165.0 (C=O). ESI-MS: m/z 497.2 [M - H]-. 
HRMS, found: m/z 521.1589, C31H22N4NaO3 requires 521.1584. IR νmax (cm-1): 3247.7 (N-H 
stretch), 3062.2, 2223.1 (C≡N stretch), 1686.3 (C=O stretch), 1603.9, 1584.6, 1523.0 (N-O 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
35 
 
asymmetric stretch), 1453.9, 1420.8, 1346.9 (N-O symmetric stretch), 1263.3, 1157.7, 
1111.7, 1076.1, 1048.1, 1014.3.   
 
5.24. 4-Benzoyl-N-(1-benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)benzamide 11 
4-Benzoylbenzoyl chloride (0.72 g, 3.0 mmol) was used. The amide 11 was obtained as a 
light yellow solid after silica gel column chromatography [EtOAc/PE (1:24) → EtOAc/PE (1: 
6)] of the crude product and recrystallisation from dichloromethane (0.16 g, 47%), m.p.: 
219.0-228.0 °C. Rf: 0.47 (30% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ (ppm): 5.06 (br 
s, 2H, NCH2Ph), 6.88-6.91 (m, 2H, Ar-H), 7.15-7.32 (m, 13H, Ar-H), 7.48 (tt, 2H, J1 = 7.6 
Hz, J2 = 1.5 Hz, Ar-H), 7.61 (tt, 1H, J1 = 7.4 Hz, J2 = 1.5 Hz, Ar-H), 7.70-7.77 (m, 6H, Ar-
H), 8.01 (br s, 1H, NHCO). 13C NMR (100 MHz, CDCl3) δ (ppm): 48.8 (NCH2Ph), 90.1 (C-
CN), 115.7 (C≡N), 123.6 (C-Ar), 126.1 (CH-Ar), 126.9 (CH-Ar), 127.6 (CH-Ar), 127.8 
(CH-Ar), 128.3 (CH-Ar), 128.5 (CH-Ar), 128.8 (CH-Ar), 128.95 (CH-Ar), 129.04 (CH-Ar), 
130.1 (CH-Ar), 130.8 (C-Ar), 131.2 (CH-Ar), 132.3 (C-Ar), 132.4 (C-Ar), 133.0 (CH-Ar), 
135.6 (C-Ar), 136.7 (C-Ar), 136.8 (C-Ar), 141.0 (C-NH2), 166.1 (C=O), 195.8 (C=O). ESI-
MS: m/z 556.2 [M - H]-.HRMS, found: m/z 580.1981, C38H27N3NaO2 requires 580.1995. IR 
νmax (cm-1): 3284.4 (N-H stretch), 3176.7, 3113.4, 3094.4, 3075.4, 3062.8, 3040.6, 3012.0, 
2230.0 (C≡N stretch), 1655.2 (C=O stretch), 1596.7, 1565.0, 1529.5, 1497.5, 1455.4, 1445.5, 
1429.7, 1319.2, 1276.5, 1182.0, 1153.4, 1077.2, 1015.9. 
 
5.25. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)-N-(3,5-dimethylbenzoyl)-3,5-
dimethylbenzamide 12 
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3,5-Dimethylbenzoyl chloride (0.47 g, 2.8 mmol) was used. The imide 12 was obtained as an 
off-white solid after silica gel column chromatography [EtOAc/PE (1:49) → EtOAc/PE 
(1:25)] of the crude product (0.22 g, 59%), m.p.: 188.4-190.2 °C. Rf: 0.71 (30% EtOAc in 
PE). 1H NMR (400 MHz, CDCl3) δ (ppm): 2.19 (s, 12H, 4 x CH3), 5.04 (br s, 2H, NCH2Ph), 
6.86-6.89 (m, 2H, Ar-H), 6.95 (br s, 2H, Ar-H), 7.05-7.07 (m, 2H, Ar-H) 7.11-7.25 (m, 15H, 
Ar-H). 13C NMR (100 MHz, CDCl3) δ (ppm): 21.0 (CH3), 48.4 (NCH2Ph), 93.0 (C-CN), 
115.2 (C≡N), 124.5, 126.4, 126.8, 126.9, 127.4, 128.3, 128.4, 128.57 128.65, 129.0, 130.3, 
131.0, 131.3, 132.2, 134.0, 134.1, 134.2, 135.7, 138.0 (C-NH2), 172.5 (C=O). ESI-MS: m/z 
636.2 [M + Na]+. HRMS, found: m/z 636.2637, C42H35N3NaO2 requires 636.2621. IR νmax 
(cm-1): 3284.4, 3116.6, 3078.6, 3062.8, 3040.6, 3012.0, 2971.0, 2945.6, 2917.1, 2866.4, 
2227.2 (C≡N stretch), 1678.0 (C=O stretch), 1606.2, 1533.4, 1495.4, 1476.4, 1453.8, 1333.5, 
1297.0, 1251.8, 1180.1, 1168.0, 1129.7, 1077.6, 1027.7.  
 
5.26. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)-3,5-dimethylbenzamide 13 
Further elution of the column [EtOAc/PE (1:49) → EtOAc/PE (1:16)] gave the amide 13 as a 
white solid (0.03 g, 10%), m.p.: 76.9-82.5 °C. Rf: 0.60 (30% EtOAc in PE). 1H NMR (300 
MHz, CDCl3) δ (ppm): 2.30 (s, 6H, 2 x CH3), 5.04 (br s, 2H, NCH2Ph), 6.88-6.92 (m, 2H, 
Ar-H), 7.15-7.31 (m, 16H, Ar-H), 7.48 (s, 1H, NHCO). 13C NMR (100 MHz, CDCl3) δ 
(ppm): 19.3 (CH3), 47.5 (NCH2Ph), 90.0 (C-CN), 115.6 (C≡N), 123.5, 125.1, 125.3, 125.9, 
126.2, 127.7, 128.6, 128.8, 129.0, 129.2, 130.5, 131.2, 132.4, 132.5, 132.7, 134.2, 136.9, 
138.5 (C-NH2), 167.1 (C=O). ESI-MS: m/z 480.2 [M - H]-. HRMS, found: m/z 504.2044, 
C33H27N3NaO requires 504.2046. IR νmax (cm-1): 3523.7 (N-H stretch), 3391.2, 3280.9, 
3189.3, 2971.7, 2918.0, 2848.6, 2760.3, 2722.5, 2485.9, 2227.2 (C≡N stretch), 1682.0 (C=O 
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stretch), 1605.4, 1586.9, 1497.1, 1447.4, 1396.9, 1345.5, 1324.7, 1260.6, 1153.4, 1100.3, 
1079.1, 1045.5, 1012.4. 
 
5.27. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)-3-nitrobenzamide 14 
3-Nitrobenzoyl chloride (0.45 g, 2.4 mmol) was used. The title compound 14 was obtained as 
a white solid after silica gel column chromatography of the crude product [EtOAc/PE (1:24) 
→ EtOAc/PE (1:6)] (0.14 g, 46%), m.p.: 221.7-227.0 °C. Rf: 0.51 (30% EtOAc in PE). 1H 
NMR (400 MHz, CDCl3) δ (ppm): 5.08 (s, 2H, NCH2Ph), 6.91-6.93 (m, 2H, Ar-H), 7.25-
7.36 (m, 13H, Ar-H), 7.56 (t, 1H, J = 7.8 Hz, Ar-H), 7.99 (d, 1H, J = 7.2 Hz, Ar-H), 8.34-
8.36 (m, 2H, Ar-H), 8.41 (br s, 1H, NHCO). 13C NMR (100 MHz, CDCl3) δ (ppm): 48.9 
(NCH2Ph), 89.9 (C-CN), 115.8 (C≡N), 122.7, 123.6, 126.0, 126.9, 127.0, 127.94, 128.3, 
128.8, 128.9, 129.0, 129.1, 129.9, 130.0, 131.0, 131.2, 132.2, 132.3, 133.6, 134.1, 136.4, 
148.1 (C-NH2), 164.6 (C=O). ESI-MS: m/z 521.2 [M + Na]+. HRMS, found: m/z 521.1570, 
C31H22N4NaO3 requires 521.1584. IR νmax (cm-1): 3243.0 (N-H stretch), 3053.7, 3031.6, 
2225.4 (C≡N stretch), 1684.3 (C=O stretch), 1602.6, 1531.3, 1505.4, 1498.1 (N-O 
asymmetric stretch), 1467.2, 1449.3, 1426.6, 1343.8 (N-O symmetric stretch), 1298.3, 
1258.8, 1223.4, 1075.5. 
 
5.28. N-(1-Benzyl-3-cyano-4,5-diphenyl-1H-pyrrol-2-yl)cyclohexanecarboxamide 15 
Cyclohexanecarbonyl chloride (0.13 g, 0.86 mmol) was used as the carboxylic acid derivative 
to condense with pyrrole 5a (0.075 g, 0.22 mmol) in the presence of TEA (0.2 mL, 0.13 g, 
1.3 mmol) in toluene (4 mL). The amide 15 was obtained as light pink solid after silica gel 
column chromatography [EtOAc/PE (1:49) → EtOAc/PE (1:12)] of the crude product (0.07 
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g, 66 %), m.p.: 207.2-216.2 °C. Rf: 0.63 (30% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 
(ppm): 1.19-1.83 (m, 10H, 5 x CH2), 2.16-2.23 (m, 1H, CHCO), 4.97 (br s, 2H, NCH2Ph), 
6.83-6.85 (m, 2H, Ar-H), 7.06 (br s, 1H, CONH), 7.13-7.30 (m, 13H, Ar-H). 13C NMR (100 
MHz, CDCl3) δ (ppm): 25.4 (CH2), 25.5 (CH2), 29.4 (CH2), 45.0 (COCH), 48.4 (NCH2Ph), 
89.7 (C-CN), 115.6 (C≡N), 123.3 (C-Ar), 125.8 (CH-Ar), 126.8 (CH-Ar), 127.6 (CH-Ar), 
128.3 (CH-Ar), 128.6 (CH-Ar), 128.7 (CH-Ar), 128.86 (CH-Ar), 128.91 (CH-Ar), 130.3 (C-
Ar), 130.4 (C-Ar), 131.1 (CH-Ar), 132.4 (C-Ar), 132.9 (C-Ar), 136.9 (C-NH2), 176.0 
(C=O). ESI-MS: m/z 482.2 [M + Na]+. HRMS, found: m/z 482.2209, C31H29N3NaO requires 
482.2203. IR νmax (cm-1): 3274.5 (N-H stretch), 2931.5 (sp3 C-H stretch), 2855.0 (sp3 C-H 
stretch), 2227.7 (C≡N stretch), 1673.3 (C=O stretch), 1602.6, 1583.7, 1567.5, 1535.3, 1496.4, 
1446.9, 1350.2, 1300.8, 1249.8, 1229.8, 1173.9, 1132.6, 1105.9, 1078.5, 1029.4, 723.0. 
 
5.29. 1-Benzyl-2-(1,3-dioxoisoindolin-2-yl)-4,5-diphenyl-1H-pyrrole-3-carbonitrile 16  
Phthalic anhydride was used as the carboxylic acid derivative (89 mg, 0.60 mmol). 
Recrystallisation of the crude product from diethyl ether afforded the title compound 16 as a 
light brown solid (0.12 g, 43%), m.p.: 207.6-209.7 °C. Rf: 0.48 (30% EtOAc in PE). 1H NMR 
(300 MHz, CDCl3) δ (ppm): 4.96 (br s, 2H, NCH2Ph), 6.82-6.85 (m, 2H, Ar-H), 7.05-7.07 
(m, 3H, Ar-H), 7.18-7.32 (m, 10H, Ar-H), 7.77 (dd, 2H, J1 = 3.0 Hz, J2 = 5.7 Hz, Ar-H), 7.86 
(dd, 2H, J1 = 3.0 Hz, J2 = 5.6 Hz, Ar-H). 13C NMR (75 MHz, CDCl3) δ (ppm): 49.1 
(NCH2Ph), 93.6 (C-CN), 114.5 (C≡N), 124.3 (Ar-CH), 124.6 (Ar-C), 126.2 (Ar-C), 126.3 
(Ar-CH), 127.0 (Ar-CH), 127.8 (Ar-CH), 128.3 (Ar-CH), 128.7 (Ar-CH), 128.8 (Ar-CH), 
128.9 (Ar-CH), 129.0 (Ar-CH), 130.0 (Ar-C), 131.2 (Ar-CH), 131.3 (Ar-C), 132.0 (Ar-C), 
132.2 (Ar-C), 134.9 (Ar-CH), 135.4 (C-NH2), 165.6 (C=O). ESI-MS: m/z 480.2 [M + H]+. 
HRMS, found: m/z 502.1527, C32H21N3NaO2 requires 502.1526. IR νmax (cm-1): 3113.6, 
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3060.0, 2226.3 (C≡N stretch), 1732.6 (C=O stretch), 1703.6 (C=O stretch), 1605.8, 1533.2, 
1505.0, 1480.7, 1457.3, 1345.1, 1325.0, 1260.3, 1077.8, 1017.0. 
 
5.30. 2-Amino-1-benzyl-4,5-diphenyl-1H-pyrrole-3-carboxamide 17 [36] 
Pyrrole 5a (0.31 g, 0.90 mmol) was stirred in a mixture of polyphosphoric acid (6.4 g 
phosphoric oxide and 4.5 mL phosphoric acid) and phosphoric acid (3.6 g, 1.9 mL). The 
reaction mixture was heated at 120 °C for 5 h, after which it was quenched with a mixture of 
ice and 25% ammonia. The addition of ammonia to the mixture was continued until a pH of 7 
was achieved. The precipitate obtained was then filtered off and recrystallised from EtOAc to 
afford the amide 17 as a dark semi-solid (0.26 g, 79%). Rf: 0.24 (30% EtOAc in PE). 1H 
NMR (400 MHz, CDCl3) δ (ppm): 4.91 (br s, 2H, NCH2Ph), 5.06 (br s, 2H, D2O 
exchangeable protons), 6.98-7.38 (m, 15H, Ar-H). 13C (100 MHz, CDCl3) δ (ppm): 46.6 
(NCH2Ph), 95.6 (CCONH2), 119.3 (Ar-C), 125.8 (Ar-C), 125.9 (Ar-CH), 127.1 (Ar-CH), 
127.7 (Ar-CH), 128.1 (Ar-CH), 128.4 (Ar-CH), 129.1 (Ar-CH), 130.6 (Ar-CH), 131.1 (Ar-
CH), 135.3 (Ar-C), 136.6 (Ar-C), 146.3 (C-NH2), 168.7 (C=O). LRMS: m/z 368.1 [M + H]+. 
HRMS, found: m/z 368.1758, C24H22N3O requires 368.1757. IR νmax (cm-1): 3165.1 (N-H 
stretch), 3061.2, 1670.7 (C=O stretch), 1597.5, 1495.9, 1448.7, 1410.9, 1274.4, 1209.9, 
1176.1, 1105.7, 1069.8, 1027.9, 1002.0. 
 
5.31. 1-Benzyl-4,5-diphenyl-3-(1H-tetrazol-5-yl)-1H-pyrrol-2-amine 18  
Trimethylsilyl azide (0.23 mL, 0.20 g, 1.7 mmol) was cautiously added to 
trimethylaluminium (2.0 M in toluene, 0.85 mL, 1.7 mmol) at 0 °C. A solution of pyrrole 5a 
(0.45 g, 1.3 mmol) in toluene (7 mL) was added dropwise to the resulting clear solution at 0 
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°C. The reaction mixture was stirred at room temperature for 30 min and then overnight at 80 
°C. The reaction mixture was cooled to 0 °C and subsequently poured into a biphasic mixture 
of EtOAc (6 mL) and 6 M HCl (6 mL). The aqueous layer was extracted with EtOAc (2 x 40 
mL) and the organic layers were combined, washed with brine, dried over anhydrous Na2SO4 
and concentrated in vacuo to afford a golden-coloured solid (0.59 g). The crude product was 
purified by silica gel column chromatography [EtOAc/PE (3:17) → EtOAc/PE (7:13)] to 
afford the tetrazole 18 as a light brown solid (0.13 g, 26%), m.p.: 184.4-191.4 oC. Rf: 0.52 
(30% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ (ppm): 5.01 (s, 2H, NCH2Ph), 5.09 (br s, 
2H, NH2, D2O exchangeable), 7.06-7.08 (m, 2H, Ar-H), 7.15-7.18 (m, 5H, Ar-H), 7.23-7.26 
(m, 2H, Ar-H), 7.29-7.40 (m, 6H, Ar-H), 10.79 (br s, 1H, tetrazole NH, D2O exchangeable). 
13C NMR (100 MHz, CDCl3) δ (ppm): 47.1 (NCH2Ph), 86.8 (C-CH=N), 118.6 (Ar-C), 125.9 
(Ar-CH), 127.0 (Ar-C), 127.5 (Ar-CH), 127.7 (Ar-CH), 127.9 (Ar-CH), 128.3 (Ar-CH), 
129.27 (Ar-CH), 129.29 (Ar-CH), 130.3 (Ar-CH), 130.5 (Ar-CH), 130.6 (Ar-C), 134.8 (Ar-
C), 136.4 (Ar-C), 142.3 (C-NH2), 151.3 (NH-CH=N); LRMS: m/z 391.1 [M - H]-. HRMS, 
found: m/z 391.1685, C24H19N6 requires 391.1677. IR νmax (cm-1): 3421.8 (N-H stretch), 
3304.8 (N-H stretch), 3217.0, 3165.1, 3061.2, 3032.0, 1683.8, 1573.8, 1497.0, 1481.1, 
1453.4, 1443.9, 1357.7, 1270.6, 1170.5, 1070.7, 1001.0. 
 
5.32. 2-Amino-4,5-diphenyl-1H-pyrrole-3-carbonitrile 19  
A solution of pyrrole 5d (0.30 g, 0.79 mmol) in anisole (5 mL) was added to a stirred 
suspension of aluminium chloride (0.53 g, 4.0 mmol) in anisole (5 mL) at 0 °C in an ice bath. 
The ice bath was then removed and the mixture was heated at 120 °C for 17 h. The reaction 
mixture was cooled to room temperature, poured into water (20 mL) and extracted with 
EtOAc (3 x 10 mL). The organic layers were collected and washed successively with 
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saturated NaHCO3 (10 mL), water (10 mL) and brine (10 mL), and dried over anhydrous 
Na2SO4. The solvent was removed in vacuo and the resulting crude product (brown oil) was 
purified by silica gel column chromatography [EtOAc/PE (1:19) → EtOAc/PE (3:7)] to give 
the title compound 19 as a dark solid (0.075 g, 36%), m.p.: 97.6-104.4 °C. Rf: 0.21 (30% 
EtOAc in PE). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 5.74 (br s, 2H, NH2, D2O 
exchangeable), 7.11-7.33 (m, 10H, Ar-H), 10.81 (br s, 1H, NH, D2O exchangeable). 13C 
NMR (100 MHz, DMSO-d6) δ (ppm): 72.9 (C-CN), 117.9 (C≡N), 119.8 (Ar-C), 119.9 (Ar-
C), 126.0 (Ar-CH), 126.3 (Ar-CH), 126.7 (Ar-CH), 128.4 (Ar-CH), 128.5 (Ar-CH), 129.0 
(Ar-CH), 131.8 (Ar-C) 134.3 (Ar-C), 148.9 (C-NH2); LRMS: m/z 258.1 [M - H]-. HRMS, 
found: m/z 258.1047, C17H12N3 requires 258.1037. IR νmax (cm-1): 3451.0 (N-H stretch), 
3373.0 (N-H stretch), 3327.5 (N-H stretch), 3272.3, 3233.3, 3210.6, 3155.4, 2203.9 (C≡N 
stretch), 1670.8, 1628.0, 1562.4, 1497.0, 1455.9, 1345.8, 1205.8, 1157.7, 1113.5, 1065.4, 
1013.2. 
 
5.33. Enzyme preparation and Kinetic Assays. IMP-1 was expressed, purified and assayed as 
described in our previous publications [25-27]. The substrate used in the assays was CENTA 
[24], a chromogenic cephalosporin derivative. Reaction rates, in the absence and presence of 
the compounds were measured by recording the release of the chromophore, monitored at 
405 nm (ε = 6400 M-1cm-1), at pH 7.0. The catalytic data were analysed using equation 1 
[53]. Here, the values of Vmax and Km are the maximum rate and Michaelis-Menten constant, 
[S] and [I] are the substrate and inhibitor concentrations, respectively. The Kic and Kiuc 
parameters are the equilibrium dissociation constants describing competitive and 
uncompetitive inhibitor binding, respectively. 
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CphA was expressed and purified as described elsewhere [54]. E. coli strain BL21(DE3) was 
used as the host for the expression of CphA. The expression plasmid PJ411::CphA 
(purchased from DNA2.0) was transformed into this recipient strain by heat shock and the 
transformants with resistance to kanamycin (50 µg/mL) were used for the over-expression of 
the recombinant protein. The protein was subsequently purified using the published 
procedure [55]. In brief, following expression the cells were lysed by sonication. The 
supernatant was loaded onto a SP-Sepharose column, pre-equilibrated with 20 mM Hepes, 
pH 7.5, supplemented with 0.15 mM ZnCl2. The protein was subsequently eluted with a 
gradient of 0-1 M NaCl. The catalytic activity of CphA was measured at pH 7.0 employing 
meropenem as substrate (ε300nm =  6500 M-1cm-1); data were analysed as described above for 
IMP-1.  
AIM-1 was expressed and purified as described in our previous publication [22]. Catalytic 
activity, in the absence and presence of compounds, were measured employing cefuroxime as 
substrate at pH 7.0 (260 nm, ε = 9320 M-1cm-1); data were analysed as described above for 
IMP-1. 
 
5.34. Biological Assays. The inhibitors were tested using E. coli BL21(DE3) cells, which 
were transformed with plasmids expressing either IMP-1, CphA or AIM-1 (blaNDM-1, CphA, 
blaAIM-1), as described previously [28]. Relevant compounds were incorporated by adsorption 
into Mueller-Hinton (MH) agar by distributing the compound on the surface of MH agar. 
Following the adsorption of the compound into the bacterial media, bacterial suspensions at 
0.5 McFarland were spread onto the agar plates. Then a meropenem E-test strip (bioMerieux) 
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was placed over the agar medium to determine minimum inhibitory concentration (MIC). The 
plates were incubated overnight and MIC values registered. As control the MICs were also 
recorded for E. coli BL21(DE3) cells in the absence of the compound. The fold differences of 
MICs between the strains tested on the plate with compound and without compound were 
calculated. We employed meropenem as substrate for biological assays.  As a representative 
of the “last line” carbapenem antibiotics it belongs to the only group of β-lactam substrates 
that is effectively inactivated by B2-type MBLs such as CphA.  Furthermore, meropenem is 
also a good substrate for IMP-1 and AIM-1 [23, 56].  Another frequently used carbapenem 
used in functional studies of MBLs is imipenem, which is inactivated by IMP-1, CphA and 
AIM-1 with a catalytic efficiency similar to that of meropenem [23, 56, 57]. 
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Captions: 
Figure 1. Chemical structure of Imipenem 1. 
Figure 2. Computational model of pyrrole 5a docked into the active site of IMP-1 as 
predicted by MolDock [32]. Atom colours: carbon on ligand in olive green, carbon on IMP-1 
in grey, nitrogen in blue, oxygen in red and hydrogen in white. The Zn2+ ions are shown as 
red spheres. The dashed, green lines represent hydrogen bonds. Adapted from [27]. 
Figure 3. Amide and imide products arising from the acylation of pyrrole 5a. Reaction 
conditions used were the same as those described in Scheme 3. 
Table 1. Inhibition data for 2-amino-3-cyanopyrroles 5a-h (10 µM) against IMP-1 activity. 
Table 2. Inhibition data for N-acyl amides and N,N-diacyl imides 7-16 (10 µM) against IMP-
1 activity. For comparison, compound 5a showed inhibition of 26% at 10 µM (Table 1). 
Table 3. Inhibition data for pyrrole derivatives 17-19 (10 µM) against IMP-1 activity. 
Table 4. Competitive (Kic) and uncompetitive (Kiuc) inhibition constants of inhibitors 5a, 7b, 
8b, 10, 11, 13 and 14 against IMP-1. 
Table 5. Comparison of inhibitory activities of compounds 5a, 8b, 10 and 11 against 
representatives of each subclass of MBL. 
Table 6. MIC values (µg/mL) for meropenem, measured in the absence (Blank) and presence 
of compounds 5a, 8b, 10 or 11. Data were measured for E. coli BL21  expressing either IMP-
1, CphA or AIM-1. 
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Scheme 1. Reagents and conditions: (a) Cl3CCO2H, toluene, ∆, 4-6 h; (b) CH2(CN)2, ∆, 
overnight. 5a (67%); 5b (61%); 5c (59%); 5d (63%); 5e (78%); 5f (53%); 5g (78%); 5h 
(0%). 
Scheme 2. Reagents and conditions: (a) Cl3CCO2H, toluene, ∆ (63%); (b) CH2(CN)2, NaOEt, 
EtOH, ∆ (60%). 
Scheme 3. Reagents and conditions: (a) (i) Ac2O, ∆, 3 h, (ii) 25% NH3, 7a (79%) or RCOCl, 
Et3N, toluene, ∆, overnight, 7b (76%); 7c (86%); 7d (93%); (b) K2CO3, MeOH, r.t., 1 h, 8a 
(68%); 8b (56%); 8c (95%); 8d (87%). 
Scheme 4. Reagents and conditions: (a) (i) P2O5, H3PO4, ∆, 5 h; (ii) 25% NH3 (79%); (b) 
TMSN3, Me3Al, toluene, ∆, 28 h (26%). 
Scheme 5. Reagents and conditions: (a) AlCl3, PhOMe, ∆, 17 h (36%). 
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• An inhibitor of all three major classes of metallo-β-lactamases is described. 
• Derivatives show potent in vitro inhibitory activity. 
• Re-sensitisation of MBL-producing bacteria towards meropenem is demonstrated. 
